A new compound, 1-[2-(2,6-dimethylphenoxy)ethyl]-alpha,alpha-bis-(p-fluorphenyl)-4 -
piperidine methanol (
LAS 30538), was found to have potent
vasodilator effects. Its
vasorelaxant activity was demonstrated in rat perfused hindlimbs contracted with 80 mM K+, having an IC50 value of 40 nM. In conscious spontaneously hypertensive rats,
LAS 30538 administered orally, caused dose-dependent sustained falls in systolic blood pressure with an ED30 value of 11 mg kg-1. In pithed rats,
LAS 30538, strongly inhibited vasoconstriction induced by the alpha 2-adrenoceptor agonist
B-HT 933 and the
calcium agonist compound
Bay K8644 with ED50 values of 4 mg kg-1 p.o. and 1.3 mg kg-1 i.v., respectively. Results from electrophysiological studies carried out using guinea-pig papillary muscles partially depolarized by 22 mM K+ are consistent with
LAS 30538 acting as a Ca(2+)-channel blocker. When compared with
verapamil, in guinea-pig and rabbit isolated heart preparations,
LAS 30538 caused less cardiodepression and
bradycardia. The results suggest that
LAS 30538 may have some advantages over other Ca(2+)-channel blockers such as
verapamil in causing less myocardial depression for a given level of vasodilatation.